Literature DB >> 2070547

Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO syndrome).

R Salonen1, M Somer, M Haltia, M Lorentz, R Norio.   

Abstract

We describe 14 patients, from 11 families, who have a progressive encephalopathy with early onset. The clinical signs of the disease are severe hypotonia, convulsions with hypsarrhythmia, profound mental retardation, hyperreflexia, transient or persistent edema, and optic atrophy. These findings and the characteristic dysmorphic features allow recognition of these patients, although no basic metabolic defect has been found. Microcephaly and atrophy of the brain develop, especially in the cerebellar and brain stem areas. An autosomal recessive mode of inheritance is likely.

Entities:  

Mesh:

Year:  1991        PMID: 2070547     DOI: 10.1111/j.1399-0004.1991.tb03027.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  17 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  A neurodevelopmental disorder caused by mutations in the VPS51 subunit of the GARP and EARP complexes.

Authors:  David C Gershlick; Morié Ishida; Julie R Jones; Allison Bellomo; Juan S Bonifacino; David B Everman
Journal:  Hum Mol Genet       Date:  2019-05-01       Impact factor: 6.150

3.  Linkage disequilibrium mapping in isolated populations: the example of Finland revisited.

Authors:  A de la Chapelle; F A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 4.  SPTAN1 encephalopathy: distinct phenotypes and genotypes.

Authors:  Jun Tohyama; Mitsuko Nakashima; Shin Nabatame; Ch'ng Gaik-Siew; Rie Miyata; Zvonka Rener-Primec; Mitsuhiro Kato; Naomichi Matsumoto; Hirotomo Saitsu
Journal:  J Hum Genet       Date:  2015-01-29       Impact factor: 3.172

Review 5.  De novo dominant variants affecting the motor domain of KIF1A are a cause of PEHO syndrome.

Authors:  Sylvie Langlois; Maja Tarailo-Graovac; Bryan Sayson; Britt Drögemöller; Anne Swenerton; Colin Jd Ross; Wyeth W Wasserman; Clara Dm van Karnebeek
Journal:  Eur J Hum Genet       Date:  2015-10-21       Impact factor: 4.246

6.  Infantile cerebello-optic atrophy. Neuropathology of the progressive encephalopathy syndrome with edema, hypsarrhythmia and optic atrophy (the PEHO syndrome).

Authors:  M Haltia; M Somer
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  PEHO syndrome caused by compound heterozygote variants in ZNHIT3 gene.

Authors:  Katrin Õunap; Kai Muru; Eve Õiglane-Shlik; Pilvi Ilves; Sander Pajusalu; Imbi Kuus; Monica H Wojcik; Tiia Reimand
Journal:  Eur J Med Genet       Date:  2019-04-29       Impact factor: 2.708

8.  Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient.

Authors:  Lydie Burglen; Sandra Chantot-Bastaraud; Catherine Garel; Mathieu Milh; Renaud Touraine; Ginevra Zanni; Florence Petit; Alexandra Afenjar; Cyril Goizet; Sabina Barresi; Aurélie Coussement; Christine Ioos; Leila Lazaro; Sylvie Joriot; Isabelle Desguerre; Didier Lacombe; Vincent des Portes; Enrico Bertini; Jean-Pierre Siffroi; Thierry Billette de Villemeur; Diana Rodriguez
Journal:  Orphanet J Rare Dis       Date:  2012-03-27       Impact factor: 4.123

9.  Diagnostic criteria and genetics of the PEHO syndrome.

Authors:  M Somer
Journal:  J Med Genet       Date:  1993-11       Impact factor: 6.318

10.  PEHO Syndrome May Represent Phenotypic Expansion at the Severe End of the Early-Onset Encephalopathies.

Authors:  Pawel Gawlinski; Renata Posmyk; Tomasz Gambin; Danuta Sielicka; Monika Chorazy; Beata Nowakowska; Shalini N Jhangiani; Donna M Muzny; Monika Bekiesinska-Figatowska; Jerzy Bal; Eric Boerwinkle; Richard A Gibbs; James R Lupski; Wojciech Wiszniewski
Journal:  Pediatr Neurol       Date:  2016-04-09       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.